Title
Gain-of-function mutation of a voltage-gated sodium channel NaV1.7 associated with peripheral pain and impaired limb development.

Permalink
https://escholarship.org/uc/item/3mr4w4s6

Journal
The Journal of biological chemistry, 292(22)

ISSN
0021-9258

Authors
Tanaka, Brian S
Nguyen, Phuong T
Zhou, Eray Yihui
et al.

Publication Date
2017-06-01

DOI
10.1074/jbc.M117.778779

Peer reviewed
Gain-of-function mutation of a voltage-gated sodium channel Na\textsubscript{\text{V}}1.7 associated with peripheral pain and impaired limb development

Received for publication, February 3, 2017, and in revised form, March 24, 2017. Published, Papers in Press, April 5, 2017. DOI 10.1074/jbc.M117.778779

Brian S. Tanaka\textsuperscript{1,5,6}, Phuong T. Nguyen\textsuperscript{1,7,8}, Eray Yihui Zhou\textsuperscript{1+5,8}, Yong Yang\textsuperscript{1+7}, Vladimir Yarov-Yarovoy\textsuperscript{1+8}, Sulayman D. Dib-Hajj\textsuperscript{1+9,8} and Stephen G. Waxman\textsuperscript{1+9,10}

From the \textsuperscript{1}Department of Neurology, the \textsuperscript{2}Center for Neuroscience \& Regeneration Research, Yale University School of Medicine, New Haven, Connecticut 06516, the \textsuperscript{3}Rehabilitation Research Center, Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut 06516, the \textsuperscript{4}Department of Physiology and Membrane Biology and the \textsuperscript{5}Biophysics Graduate Group, University of California, Davis, California 95616, the \textsuperscript{6}Department of Dermatology, Peking University First Hospital, Beijing 100034, China, and the \textsuperscript{7}Department of Dermatology, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing 102218, China

Edited by F. Anne Stephenson

Dominant mutations in voltage-gated sodium channel Na\textsubscript{\text{V}}1.7 cause inherited erythromelalgia, a debilitating pain disorder characterized by severe burning pain and redness of the distal extremities. Na\textsubscript{\text{V}}1.7 is preferentially expressed within peripheral sensory and sympathetic neurons. Here, we describe a novel Na\textsubscript{\text{V}}1.7 mutation in an 11-year-old male with underdevelopment of the limbs, recurrent attacks of burning pain with erythema, and swelling in his feet and hands. Frequency and duration of the episodes gradually increased with age, and relief by cooling became less effective. The patient’s sister had short stature and reported similar complaints of erythema and burning pain, but with less intensity. Genetic analysis revealed a novel missense mutation in Na\textsubscript{\text{V}}1.7 (2567G\textrightarrow{}C; p.Gly856Arg) in both siblings. The G856R mutation, located within the DII/S4-S5 linker of the channel, substitutes a highly conserved non-polar glycine by a positively charged arginine. Voltage-clamp analysis of G856R currents revealed that the mutation hyperpolarized (−11.2 mV) voltage dependence of activation and slowed deactivation but did not affect fast inactivation, compared with wild-type channels. A mutation of Gly-856 to aspartic acid was previously found in a family with limb pain and limb underdevelopment, and its functional assessment showed hyperpolarized activation, depolarized fast inactivation, and increased ramp current. Structural modeling using the Rosetta computational modeling suite provided structural clues to the divergent effects of the substitution of Gly-856 by arginine and aspartic acid. Although the proexcitatory changes in gating properties of G856R contribute to the pathophysiology of inherited erythromelalgia, the link to limb underdevelopment is not well understood.

The Na\textsubscript{\text{V}}1.7 sodium channel is preferentially expressed in sensory and sympathetic neurons (1–4) and their axons (5). Na\textsubscript{\text{V}}1.7 is expressed in small neurons in dorsal root ganglion (DRG), giving rise to unmyelinated peripheral nerve fibers, which have a functional role in pain signal propagation from receptive fields to the first synapse in the dorsal horn of the spinal cord (3,4). Na\textsubscript{\text{V}}1.7 is considered a threshold channel for its ability to boost subthreshold stimuli and set the gain of DRG neurons (6). More than 20 dominant gain-of-function mutations in SCN9A encoding Na\textsubscript{\text{V}}1.7 have been linked to inherited erythromelalgia (IEM) with the vast majority hyperpolarizing activation, slowing deactivation, slowing rates of closed-state inactivation, and increasing the response to slow ramp depolarizations (7–10). Gain-of-function Na\textsubscript{\text{V}}1.7 mutations have also been linked to small-fiber neuropathy (11–14), which is characterized by neuropathic pain and autonomic dysfunction (15). In contrast, recessive loss-of-function mutations of Na\textsubscript{\text{V}}1.7 underlie congenital insensitivity to pain (16–18). These studies provide compelling evidence that Na\textsubscript{\text{V}}1.7 channels are critical for pain-signal transmission.

IEM is characterized by episodic reddening and burning pain of the hands and feet, triggered by mild warmth or exercise (19, 20). Most subjects manifest painful symptoms early in childhood (infancy to 6 years of age); however, occasionally some families show late-onset of symptoms (19–21). Gain-of-function mutations of the Na\textsubscript{\text{V}}1.7 channel have been shown to render DRG neurons hyperexcitable, providing the cellular correlate for neuropathic pain in patients with IEM (7, 10, 19). A mutation of Na\textsubscript{\text{V}}1.7, G856D, was previously found in a family with IEM-like symptoms, dysautonomia, and small hands and small feet (14). Functional assessment of G856D mutant channels showed hyperpolarized activation and depolarized fast inactivation, and the expression of G856D channels in DRG neurons rendered these neurons hyperexcitable, suggesting that in addition to causing pain symptoms, peripheral nerve dysfunction may contribute to limb underdevelopment in this novel syndrome (14).
In this study, we describe a kindred with IEM symptoms including erythema, burning pain in the distal extremities, and underdevelopment of the limbs. We report a novel mutation in \( \text{SCN9A} \) (c.2567G\( \rightarrow \)H11022C; \( p.\text{Gly856Arg} \)) that produces functional changes including hyperpolarized voltage dependence of activation and slower deactivation but does not affect fast inactivation. We also report results from the Rosetta computational modeling suite to gain structural clues to the effects of the substitution of Gly-856 by arginine and aspartic acid.

**Results**

*Clinical phenotype and identification of the G856R mutation*

An 11-year-old male presented with limb pain and underdevelopment of the limbs. He experienced recurrent attacks of bilateral and symmetrical intense warmth, redness, pain, and swelling involving the hands and feet. Almost all of his anthropometric measurements fell below the age- and gender-matched 5th percentile cutoff with several measurements below the 5th percentile cutoff (Table 1). At the age of 5, he noted episodes of burning pain with erythema and swelling in his feet, but his hands were less affected. The symptoms were exacerbated during the summer. Prolonged sock- or shoe-wearing triggered burning pain attacks. As the proband got older, there was a gradual increase in frequency and duration of the episodes, and the burning pain could not be effectively relieved by cooling. Immersion of his feet in cold water for an extended period of time led to painful skin lesions. There were no signs of large fiber involvement. Repeated laboratory tests demonstrated thrombocytosis (platelet count 5.90\( \times \)10\(^{12} \)/liter). Treatment with aspirin, propranolol, carbamazepine, gabapentin, pregabalin, misoprostol, and venlafaxine were not effective.

The patient’s sister (aged 17 years at the time of examination) presented with more severe underdevelopment of the limbs. He experienced recurrent attacks of bilateral and symmetrical intense warmth, redness, pain, and swelling involving the hands and feet. Almost all of his anthropometric measurements fell below the age- and gender-matched 1st percentile cutoff (Table 1). At the age of 5, he noted episodes of burning pain with erythema and swelling in his feet, but his hands were less affected. The symptoms were exacerbated during the summer. Prolonged sock- or shoe-wearing triggered burning pain attacks. As the proband got older, there was a gradual increase in frequency and duration of the episodes, and the burning pain could not be effectively relieved by cooling. Immersion of his feet in cold water for an extended period of time led to painful skin lesions. There were no signs of large fiber involvement. Repeated laboratory tests demonstrated thrombocytosis (platelet count 5.90\( \times \)10\(^{12} \)/liter). Treatment with aspirin, propranolol, carbamazepine, gabapentin, pregabalin, misoprostol, and venlafaxine were not effective.

The patient’s sister (aged 17 years at the time of examination) presented with more severe underdevelopment of the limbs and similar symptoms (Fig. 1A). The majority of her anthropometric measurements, including hand and foot length, fell below the age- and gender-matched 1st percentile (Table 1). The erythema and burning pain were not as intense as in the proband. However, her physical development significantly lagged behind her typical peers, and she was of small stature (Table 1). She had primary amenorrhea, and secondary sexual characteristics were absent. Her serum levels of luteiniz-

### Table 1

**Anthropometric measurements**

<table>
<thead>
<tr>
<th>Measure</th>
<th>Mean (11–12-year-old male)</th>
<th>5th percentile cut-off (11–12 years male)</th>
<th>Brother/% value</th>
<th>Mean (16–17-year-old female)</th>
<th>5th percentile cut-off (16–17 years female)</th>
<th>Sister/% value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Height (cm)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stature</td>
<td>1466</td>
<td>1350</td>
<td>1420/25</td>
<td>1590</td>
<td>1501</td>
<td>1410/1*</td>
</tr>
<tr>
<td>Shoulder height sitting</td>
<td>498</td>
<td>448</td>
<td>470/20</td>
<td>567</td>
<td>524</td>
<td>445/1*</td>
</tr>
<tr>
<td>Elbow height sitting</td>
<td>206</td>
<td>170</td>
<td>160/2*</td>
<td>249</td>
<td>209</td>
<td>170/1*</td>
</tr>
<tr>
<td>Forearm length</td>
<td>202</td>
<td>177</td>
<td>215/78</td>
<td>217</td>
<td>194</td>
<td>195/6</td>
</tr>
<tr>
<td>Hand length</td>
<td>160</td>
<td>145</td>
<td>150/20</td>
<td>170</td>
<td>157</td>
<td>150/1*</td>
</tr>
<tr>
<td>Hand width (without thumb)</td>
<td>72</td>
<td>65</td>
<td>66/7.5</td>
<td>74</td>
<td>68</td>
<td>67/3*</td>
</tr>
<tr>
<td>Buttock-popliteal distance</td>
<td>367</td>
<td>416</td>
<td>360/2.5*</td>
<td>459</td>
<td>410</td>
<td>380/1*</td>
</tr>
<tr>
<td>Buttock-knee distance</td>
<td>500</td>
<td>448</td>
<td>430/1*</td>
<td>548</td>
<td>509</td>
<td>440/1*</td>
</tr>
<tr>
<td>Popliteal height</td>
<td>367</td>
<td>324</td>
<td>395/85</td>
<td>379</td>
<td>346</td>
<td>380/51</td>
</tr>
<tr>
<td>Foot length</td>
<td>228</td>
<td>206</td>
<td>223/37.5</td>
<td>231</td>
<td>213</td>
<td>195/1*</td>
</tr>
<tr>
<td>Foot width</td>
<td></td>
<td>69</td>
<td>78/25</td>
<td>83</td>
<td>70</td>
<td>80/40</td>
</tr>
</tbody>
</table>

**Note:** The asterisk symbols (*) are <5th percentile cut-off normative values.

---

**Figure 1.** G856R mutation in DI/S4-S5 linker of Na\(_{\text{V}}\)1.7 in IEM. A, family pedigree showing affected siblings with asymptomatic mother. Squares denote males; circles denote females. Filled symbols denote clinically affected individuals with erythromelalgia. The half-filled circle indicates the mother who experienced transient burning sensation as a teenager. Subjects identified with the novel G856R mutation are denoted with a (\(\dag\)) symbol. The proband is indicated by an arrow. B, sequence alignment and position of the G856R residue within the S4-S5 linker II of the Na\(_{\text{V}}\)1.7 channel. The G856R mutation substitutes a highly conserved glycine to an arginine.
ing hormone, follicle-stimulating hormone, estradiol, and progesterone were similar to follicular-phase hormone levels of a healthy adult woman. Other laboratory examinations including growth hormone and thyroid hormone levels tests were unremarkable.

The parents and the eldest sister did not manifest any pain symptoms, and their physical examination was unremarkable. The same examiner of the patients conducted anthropometric measurements of the parents, and the results fell within range of ethnically matched adults. However, the mother recalled transient burning sensations during her teenage years. DNA analysis showed a new SCN9A variant (c.2567G>C) in both affected siblings. Sequence analysis of the mother (blood and saliva) suggested a possible mosaicism for this mutation.

This c.2567G>C variant substitutes a highly conserved non-polar glycine with an arginine at position 856 of Na\textsubscript{v}1.7 (p.Gly856Arg) within the DII/S4-S5 linker (Fig. 1B).

**G856R mutation hyperpolarized the voltage dependence of activation**

The effects of the mutation on Na\textsubscript{v}1.7-gating properties were assessed using voltage-clamp recordings after transient transfection of HEK293 cells with WT or G856R mutant channels together with h\textsubscript{\beta}1 and h\textsubscript{\beta}2 subunits. Representative inward sodium current trace families from cells expressing WT and G856R are shown in Fig. 2A. Fig. 2B shows that the average peak current density of G856R channels (557 ± 65 pA/pF; n = 22) was significantly greater than WT channels (366 ± 48 pA/pF; n = 19, \( p < 0.05 \)). G856R mutant channels activated and reached maximal amplitudes at more hyperpolarized potentials compared with WT channels (Fig. 2C). The midpoint of the voltage dependence of activation of G856R mutant channels (G856R: -28.4 ± 1.3 mV, n = 18, \( p < 0.05 \)) is significantly shifted in the hyperpolarized direction compared with WT
channels (WT: −17.2 ± 1.1 mV, n = 17; Fig. 2D) without a change in the slope (WT: 8.2 ± 0.3, n = 17; G856R: 8.3 ± 0.3, n = 18; p > 0.05).

The voltage dependence of steady-state fast inactivation of G856R mutant channels was not significantly different from WT channels (WT: −80.2 ± 1.4 mV, n = 23; G856R: −82.7 ± 1.1 mV, n = 17; Fig. 2D). The slope of the steady-state inactivation curve for G856R (8.1 ± 0.3, n = 17) was not significantly different from the slope for WT channels (7.9 ± 0.2, n = 23; Fig. 2D).

Deactivation reflects the transition from the open state to the closed state of WT and G856R channels and was examined by eliciting tail currents at a range of voltages (−120 to −40 mV) after briefly depolarizing to −10 mV for 0.5 ms. The G856R mutation significantly slows the deactivation rate of sodium currents at all tested potentials (Fig. 3A). The time constant of deactivation of the mutant channel at −40 mV was almost 5-fold larger than that of WT channels (WT: 0.22 ± 0.02 ms, n = 20; G856R: 1.09 ± 0.08 ms, n = 15; p < 0.05).

We assessed the effect of the G856R mutation on slow inactivation by stepping from a membrane potential of −120 mV to a series of 30-s prepulses (−130 to +10 mV) followed by a 100-ms pulse to −120 mV to allow recovery from fast inactivation and then applying a 20-ms depolarizing step to −10 mV to determine the fraction of available current. Slow inactivation was enhanced for G856R mutant channels (Fig. 3B), with the midpoint significantly hyperpolarized by 9.2 mV (WT: −76.9 ± 1.6 mV, n = 12; G856R: −86.1 ± 1.6 mV, n = 11; p < 0.05). The

Figure 3. Deactivation is slowed by the G856R mutation. A, deactivation time constants for WT and G856R channels. Tail currents were elicited by a brief 0.5-ms depolarization to −10 mV followed by a series of hyperpolarizing pulses ranging from −120 to −40 mV from a holding potential of −120 mV. Current decay of the tail current was fitted with a single exponential equation and plotted as a function of the hyperpolarizing step. B, comparison of steady-state slow inactivation for WT (black squares; n = 12) and G856R (red circles; n = 11) channels. Slow inactivation was assessed with 30-s prepulses that varied from −130 to +10 mV, followed by a brief hyperpolarization (−120 mV for 100 ms) to remove fast inactivation and a depolarizing test pulse to −10 mV to determine the fraction of available current. Peak inward currents were normalized and plotted as a function of the prepulse membrane potential and fit with a Boltzmann function. C, similar time constants for development of closed-state inactivation between WT (black squares) and G856R (red circles) channels. D, representative ramp currents in response to slow depolarizations (0.2 mV/ms) that were normalized to the peak current acquired during the activation protocol and plotted as a function of membrane potential for WT (black squares) and G856R (red circles) channels.


**Na\textsubscript{v}1.7 mutation in pain and underdevelopment of the limbs**

Table 2

<table>
<thead>
<tr>
<th>( \text{Na}_{v}1.7 )</th>
<th>(-80 \text{ mV})</th>
<th>(-70 \text{ mV})</th>
<th>(-60 \text{ mV})</th>
<th>(-50 \text{ mV})</th>
<th>( n )</th>
<th>% of peak</th>
<th>Peak voltage</th>
<th>% of peak</th>
<th>% of peak</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>83.1 (\pm) 8.7</td>
<td>61.0 (\pm) 7.6</td>
<td>33.6 (\pm) 7.0</td>
<td>17.8 (\pm) 3.5</td>
<td>8</td>
<td>0.68 (\pm) 0.10</td>
<td>31.6 (\pm) 4.2</td>
<td>0.39 (\pm) 0.11</td>
<td>0.34 (\pm) 0.08</td>
</tr>
<tr>
<td>G856R</td>
<td>89.4 (\pm) 19.1</td>
<td>57.9 (\pm) 9.7</td>
<td>27.3 (\pm) 4.5</td>
<td>10.3 (\pm) 0.9</td>
<td>7</td>
<td>0.89 (\pm) 0.12</td>
<td>38.3 (\pm) 1.9</td>
<td>0.49 (\pm) 0.10</td>
<td>0.39 (\pm) 0.08</td>
</tr>
<tr>
<td>WT</td>
<td>77.9 (\pm) 5.4</td>
<td>65.8 (\pm) 4.6</td>
<td>41.2 (\pm) 4.1</td>
<td>20.7 (\pm) 2.6</td>
<td>9</td>
<td>0.73 (\pm) 0.1</td>
<td>39.6 (\pm) 1.3</td>
<td>0.32 (\pm) 0.11</td>
<td>0.13 (\pm) 0.06</td>
</tr>
<tr>
<td>G856D</td>
<td>114.9 (\pm) 0.1</td>
<td>130.9 (\pm) 10.4</td>
<td>82.9 (\pm) 12.6</td>
<td>25.2 (\pm) 4.8</td>
<td>8</td>
<td>8.4 (\pm) 0.5</td>
<td>50.6 (\pm) 1.1</td>
<td>3.51 (\pm) 0.91</td>
<td>1.21 (\pm) 0.25</td>
</tr>
</tbody>
</table>

* \( p \leq 0.05 \) versus WT channels.

The slope for G856R (7.6 \(\pm\) 0.4, \( n = 11; p < 0.05 \)) was significantly steeper than WT (12.1 \(\pm\) 0.7, \( n = 12 \)).

Recovery from fast inactivation (repriming) of WT and G856R mutant channels was assessed using a two-pulse protocol with varied interpulse interval (1–2049 ms) at different recovery potentials (–120, –110, –100, –90, and –80 mV). The repriming rate of G856R mutant channels did not change at the test potentials when compared with WT channels (data not shown).

The development of closed-state inactivation was examined at different potentials (–80, –70, –60, and –50 mV), and the time constants were found to be similar between WT and G856R mutant channels (Fig. 3C).

Slower closed-state inactivation kinetics has been suggested to contribute to enhanced peak ramp currents (22) and has previously shown to be the case with G856D mutant channels (14). We examined the currents elicited in WT and G856R channels by slow ramp depolarizations (0.2 mV/ms; depolarization from –120 to 0 mV over 600 ms). As expected, the similar closed-state inactivation kinetics observed for WT and G856R mutant channels did not lead to altered peak ramp currents. The ramp current, expressed as a percentage of peak current, was not significantly different between WT and G856R channels (WT: 0.68 \(\pm\) 0.10%, \( n = 18 \); G856R: 0.89 \(\pm\) 0.12%, \( n = 21 \)) (Fig. 3D).

A notable feature of a previously described pain causing mutation, \( \text{Na}_{v}1.7 \)-G856D, was enhanced persistent current amplitude (14). We assessed the effect of the G856R mutation on persistent currents and found no significant change in persistent current amplitude at all measured voltages (Table 2).

**Structural modeling of the wild-type and mutant \( \text{Na}_{v}1.7 \) channels**

Here, we show that the G856R mutation enhances activation and slows deactivation similar to the previously reported mutation G856D (14). However, G856R and G856D mutant channels display divergent properties in terms of current density, steady-state fast inactivation, closed-state inactivation, and amplitude of ramp current. To explore structural differences between G856D and G856R channels that might underlie these divergent gating properties, we generated a structural model of the human \( \text{Na}_{v}1.7 \) channel using the Rosetta computational modeling suite (Fig. 4A). Our models suggest that mutant side chains at position 856 are facing toward the lipid environment (Fig. 4A).

The bulky side chain of arginine in the G856R channel markedly increases the proximity of voltage-sensing domain I (VSD-I) to transmembrane segment S5 of domain II and introduces potential steric hindrance with the side chains of Met-130 and Met-133 in DI/S1 (Fig. 4, B and C). The relatively smaller side chain of aspartic acid in the G856D channel is unhindered by neighboring residues (Fig. 4, D and E). The X-ray crystallographic structure of \( \text{Na}_{v}1.7 \)-Ab-h\( \text{Na}_{v}1.7 \)-VSD-IV chimera shows a phosphatidylcholine (23) bound to the same region of the structure where Gly-856 is positioned in our structural model. Interaction of the phosphodiester head groups of lipids are essential for voltage-dependent gating (24, 25), suggesting that alteration of the lipid-channel interaction may modulate \( \text{Na}_{v}1.7 \) channel function.

Taken together, structural modeling of G856R and G856D channels predicts that substitutions of Gly-856 by arginine or aspartic acid introduces divergent effects on the proximity of transmembrane segment DI/S5 and DI/S1, as well as disruption of lipid-channel interaction near Gly-856.

**Discussion**

The \( \text{Na}_{v}1.7 \) sodium channel plays a major role in regulation of neuronal excitability of peripheral sensory and sympathetic neurons (2, 26) and has been shown to cause a spectrum of pain disorders (10, 27). We report here the second case of a pain syndrome in which subjects with burning pain in distal limbs caused by a mutation in \( \text{Na}_{v}1.7 \) also manifest underdevelopment of hands and feet. Genetic analysis revealed a novel missense mutation in two siblings that produces a substitution of glycine with arginine (G856R) at codon 856 in the \( \text{Na}_{v}1.7 \) sodium channel. To date, five mutations within the DI/S4-S5 linker of sodium channels have been linked to human painful disorders, including IEM and small-fiber neuropathy; however, only mutations at the Gly-856 residue are associated with limb underdevelopment (9, 14, 28–30).

IEM mutations in \( \text{SCN9A} \) reported to date hyperpolarize activation of \( \text{Na}_{v}1.7 \) channels and produce hyperexcitable DRG neurons (7, 10, 19). Thus, we predict that hyperpolarized activation of G856R mutant channels will render DRG neurons hyperexcitable in response to graded stimuli and contribute to the pain phenotype in the two affected siblings. The mother of the proband was clinically asymptomatic but displayed genetic mosaicism for the G856R substitution and may have transmitted the mutant allele to her affected children. An individual with a mosaic genotype carries a mutation in all cells descended from the initial cell that acquired this mutation during embryonic development. Although the mother did not report complaints of pain as an adult, she recalled transient burning pain symptoms as a teenager. This suggests that she acquired the mutation late in embryogenesis and that she is carrying it in a small number of cells as an adult. Mosaic individuals carrying
other Na\textsubscript{v}1.7 mutations have recalled burning pain as a youth and describe markedly improved symptoms as adults (29, 31), which suggests the presence of the mutation in a smaller number of sensory neurons, compared with their affected children.

The role of sodium channels in limb development in humans is not fully understood. The subjects in this study presented with underdevelopment of the limbs together with symptoms of IEM. Remarkably, the subjects carrying the G856R mutation manifest impaired limb development, especially of the hands and feet, as previously reported in patients with the G856D mutation (14). The majority of the proband’s anthropometric measurements fell below the age- and gender-matched 25th percentile cutoff with several measurements below the 5th percentile cutoff. The proband’s sister presented with more severe underdevelopment of the limbs, including anthropometric measurements below the 1st percentile cutoff and short stature. Notably, previously reported patients with the G856D mutation (14) displayed small hands and feet.

Underdevelopment of the limbs has not been reported as a common feature in patients with IEM mutations, but there is no systemic anthropometric data available. One of the authors (Y. Y.) has clinical experience with patients carrying other Na\textsubscript{v}1.7 mutations associated with IEM but has not identified other families or singleton cases of IEM who manifest underdevelopment of the limbs. As is a common practice, precise anthropometric measurements are not implemented, except when the patients are noticeably beyond average for their age and gender group, as was the case here. Nevertheless, the Gly-856 residue reported in this study and by Hoeijmakers et al. (14) suggests that gain-of-function attributes of Na\textsubscript{v}1.7

Figure 4. Structural models of domain II S4-S5 linker region of WT-Na\textsubscript{v}1.7 and G856R mutant channels. A, transmembrane view of the human Na\textsubscript{v}1.7-G856R structural model. B, close-up view toward the membrane of G856R. C, view from the intracellular side showing unfavorable clashes with side chains of Met-130 and Met-133 in DI/S1. D, close-up view toward the membrane of the human Na\textsubscript{v}1.7-G856D model. E, view from the intracellular side. G856R and G856D are shown in space-filling representation and labeled.
at this residue may contribute to underdevelopment of the limbs.

We cannot exclude the possibility that impaired physical development in the subjects with mutations at Gly-856 is the result of a second mutation, representing a case of digenic inheritance. The simplest cases of digenic disorders typically include mutations in different subunits of a multimeric protein or mutations in genes within a biological pathway (32). Bones are innervated by sensory and sympathetic nerves to regulate local bone metabolism (33, 34). Sodium channels have been shown to be expressed in non-excitable cells, such as Schwann cells and glial cells (35–37), and expression of Na\textsubscript{v}1.2 channels has been reported in osteoblasts during embryogenesis (38). Bone resorption has been reported to be increased following sensory nerve denervation in adult rats (39). Dynamic interactions of small myelinated and unmyelinated sensory and sympathetic nerves with osteoclastic and osteoblastic cells play important roles in bone remodeling (33, 34, 40). Nerve fibers at the epiphysis of the bone has been suggested to be involved with bone growth at the epiphyseal growth plate (41, 42), thus raising the possibility that peripheral nerve dysfunction may affect limb morphogenesis during development. Because the underdevelopment of limbs is not a common feature in patients with IEM mutations, we would also have to speculate that mutations at the Gly-856 position are altering a non-canonical function of Na\textsubscript{v}1.7 or that this residue is the site of interaction with a factor that is important in the signaling cascade of limb morphogenesis.

The G856R mutation substitutes a highly conserved neutral glycine with a large positively charged arginine residue within the DII/S4-S5 linker (Fig. 1). Similar to the G856D mutation previously reported by Hoeijmakers et al. (14), G856R mutant channels hyperpolarize the voltage dependence of activation and significantly slow deactivation kinetics (Table 3), which is expected to increase the availability of channels for activation. In contrast to G856D, we show here that a change in charge residue at codon 856 did not enhance the persistent current or the response to slow ramp depolarizations (Table 2). Consistent with unchanged persistent current and peak ramp current, the rate of closed-state inactivation was unaltered in G856R mutant channels (Table 2). The divergent effects of substitutions of Gly-856 by arginine or aspartic acid on current density, fast inactivation, and persistent and ramp currents are not intuitively explained by the replacement of the neutral charge by either a positive or a negative charge.

The interaction between cell membrane phospholipids with voltage-gated channels has been suggested to provide energetic stability and proper functioning of these channels (23–25, 43). Rosetta structural modeling and predictions from the X-ray crystal structure of Na\textsubscript{v}Ab-hNa\textsubscript{v}1.7-VSD-1V chimera show a phosphatidylcholine bound (23) to the same region of the structure where Gly-856 is positioned. G856D and G856R mutations may differentially regulate channel gating because of displacement of specific lipid molecule(s) near the S4-S5 linker and S5 at the intracellular face of the plasma membrane. Sequence alignment of human, bacterial, and insect voltage-gated sodium channels in the S4-S5 linkers highlight the conservation among species at the corresponding position of Gly-856 with hydrophobic or polar amino acids and the absence of charged residues that could potentially alter lipid-channel interaction near this residue (supplemental Fig. S1). Structural modeling of the G856R mutation predicts favorable interactions with lipid phosphate groups and/or stabilizes the channel at the plasma membrane, resulting in increased current density. By contrast, G856D is predicted to cause electrostatic repulsion with lipid phosphate groups and destabilize correct transmembrane topology, thus decreasing current density. These potential divergent effects of introducing a positive or a negative charge at the 856 position on the lipid-channel interaction may underlie the opposing effects of the G856R and G856D mutations on current density.

G856R may attract new lipid molecules that do not introduce significant effect on steady-state fast inactivation, ramp current, persistent current, or closed-state inactivation. In contrast, electrostatic repulsion of a negatively charged aspartic acid in G856D mutation may prevent lipid phosphate groups from binding near the Gly-856 region leading to destabilization of the DII/S4-S5 linker and enhanced persistent current and ramp current, as well as slower rate of closed-state inactivation (14). Destabilization of the channel-lipid interaction near DII/S4-S5 linker of G856D channels may also contribute to impairment of steady-state fast inactivation reported by Hoeijmaker et al. (14). As predicted in our model, charged residues (arginine and aspartic acid) at Gly-856 may displace a specific lipid molecule(s) near DII/S4-S5 linker and transmembrane segment S5 at the intracellular side of the membrane. This disruption of lipid interaction near Gly-856 may lower the energy barrier of the early gating process leading to a shift in voltage dependence of channel activation.

To generate the human Na\textsubscript{v}1.7 channel model, we used Rosetta structural modeling suite and bacterial Na\textsubscript{v}Rh structure in a preopen or inactivated state (Protein Data Bank code 4DXW) (44) as a template (see Experimental Procedures). We compared recently published cryoEM structure of a voltage-
Na\textsubscript{v}1.7 mutation in pain and underdevelopment of the limbs

gated sodium channel from cockroach (Na\textsubscript{v}PaS) in the closed-state (45) to our structural model based on the bacterial Na\textsubscript{v}Rh crystal structure. The side chain of Val-642 in the Na\textsubscript{v}PaS structure is fully exposed to the lipid environment as predicted for Gly-856 in our hNa\textsubscript{v}1.7 model (supplemental Fig. S2). Once new Na\textsubscript{v} channel structures captured in different states become available, we may potentially gain new insights into molecular mechanism of G856D and G856R mutations.

In summary, our results indicate that this novel IEM-associated G856R mutation enhances activation and slows deactivation but imparts no change in the voltage dependence of inactivation, persistent current amplitude, or response to slow ramp depolarizations. Further studies will be needed to identify the specific lipid molecule(s) interacting with residue Gly-856 and disrupting channel gating in G856D and G856R mutant channels. Together with the mutation G856D (14), which was also associated with impaired distal limb development, these results support the conclusion that a gain-of-function mutation of Na\textsubscript{v}1.7 channels expressed in small sensory nerve fibers may adversely affect bone morphogenesis during development.

Experimental procedures

Patients

The male proband was 11 years old at the time of the first examination. He presented with recurrent attacks of bilateral and symmetrical intense warmth, redness, pain, and swelling involving the hands and the feet since the age of 5 years. The proband’s sister, age 17 years at the time of examination, presented with similar symptoms and signs.

Anthropometric measurements

Eleven anthropometric body dimensions of the proband, the proband’s sister, and their parents were measured strictly following the methods introduced by the Chinese national standard for measuring human dimensions of Chinese minors (46). Measurements were performed twice and conducted by one observer (E. Y. Z.). The findings were compared with the measurements of age- and gender-matched Chinese healthy minors reported in the same standard (46).

DNA analysis

Genomic DNA from the proband and his affected and unaffected family members was screened for mutations in SCN9A. Coding exons were amplified and compared with the reference Na\textsubscript{v}1.7 cDNA to identify sequence variation, as described previously (47).

Plasmid and transfection

The plasmid carrying the tetrodotoxin-resistant version of human Na\textsubscript{v}1.7 cDNA (WT; hNa\textsubscript{v}1.7R) was described previously (48). The hNa\textsubscript{v}1.7R-G856R mutation was introduced into hNa\textsubscript{v}1.7R using QuikChange XL site-directed mutagenesis (Stratagene), which is hereinafter referred to as G856R. WT or G856R mutant channels were co-transfected with plasmids pCD8-IRE5-h\beta1 and pEGFP-h\beta2 (49), which encode the human \beta1 and \beta2 subunits, into HEK293 cells using Lipofectamine 2000 (Invitrogen). HEK293 cells were grown under standard tissue culture conditions (5% CO\textsubscript{2}; 37 °C) in DMEM/F12 supplemented with 10% fetal bovine serum for 18 h before electrophysiological assessment.

Voltage-clamp recording

Whole-cell patch-clamp recordings were obtained from on GFP-labeled HEK293 cells using an EPC10-double amplifier and Patchmaster software (HEKA Electronik) at room temperature (20 ± 1 °C). The extracellular solution contained 140 mM NaCl, 3 mM KCl, 1 mM MgCl\textsubscript{2}, 1 mM CaCl\textsubscript{2}, 10 mM HEPES, and 10 mM dextrose, pH 7.3, adjusted with NaOH (319 mOsm). Tetrodotoxin (500 nm) was included in the bath to block endogenous sodium currents in HEK293 cells (27, 50). The pipette solution contained the following 140 mM CsF, 1 mM EGTA, 10 mM NaCl, 10 mM HEPES, and 10 mM dextrose, pH 7.3, adjusted with CsOH (adjusted to 311 mOsm with sucrose). Patch pipettes were fabricated from borosilicate glass (1.65/1.1, OD/ID; World Precision Instruments) using a Sutter Instruments P-97 puller and had a resistance of 0.8–1.3 megohm. HEK293 cells were held at −120 mV for all parameters examined. To minimize voltage errors 80–90% series resistance compensation was applied. Voltage-clamp recordings were acquired 5 min after establishing whole-cell configuration to allow steady-state dialysis between the cytoplasm and pipette solution. Recordings were acquired at 2.9 kHz with low-pass Bessel filter and digitized at 50 kHz. Linear leak and residual capacitance artifacts were removed using P/6 subtraction. The data were analyzed offline with FitMaster (HEKA Electronik), Excel (Microsoft), and Origin (Microcal Software, Northampton, MA) software.

To measure current-voltage (I-V) relationships, a range of potentials from −80 to +40 mV in 5-mV increments were applied from the holding potential (−120 mV) for 100 ms at 5-s intervals. The current density was calculated by normalizing maximal peak currents with cell capacitance. Peak inward currents obtained from activation protocols were converted to conductance values using the equation, 

$$G = G_{\text{min}} + (G_{\text{max}} - G_{\text{min}})/(1 + \exp[V_m - V_{1/2}]/k]$$

(Eq. 1)

where $V_{1/2}$ is the midpoint of activation, and $k$ is the slope factor. Steady-state fast inactivation was assessed with a series of 500-ms prepulses (−140 to 0 mV in 10-mV increments) followed by a 20-ms step depolarization to −10 mV to activate the remaining non-inactivated channels. Peak inward currents from steady-state fast inactivation were normalized by the maximum current amplitude and fit with a Boltzmann equation,

$$I = I_{\text{min}} + 1/(1 + \exp[V_m - V_{1/2}]/k]$$

(Eq. 2)

where $I$ is the current amplitude measured during the test depolarization, $V_{1/2}$ is the midpoint of fast inactivation, and $k$ is the slope factor.
Na\textsubscript{v}1.7 mutation in pain and underdevelopment of the limbs

Deactivation was estimated from current decay, using a 0.5-ms short depolarization pulse to −10 mV followed by a 50-ms repolarization pulse to potentials ranging from −40 to −120 mV in 5-mV increments. Deactivation kinetics were calculated by fitting the decaying currents with a single exponential equation,

\[ I = A \times (\exp[-t/\tau]) + C \]  

(Eq. 3)

where \( I \) is the current, \( A \) represents amplitude of the fit, \( \tau \) is the time constant, and \( C \) is the steady-state asymptote. The time shift was manually selected by fitting the traces at the time when the currents were just starting to exponentially decrease. Inactivation time constants were determined by fitting the rising phase of the current traces with a single exponential equation. Time constant of decay (\( \tau \)) were obtained from the traces at potentials −40 to +40 mV for WT and G856R channels.

Steady-state slow inactivation was assessed with 30-s prepulses at a range of potentials from −130 to +10 mV in 10-mV increments, followed by 100-ms pulse to −120 mV to allow recovery from fast-inactivation and then a 20-ms depolarizing step to −10 mV to elicit a test response, which reflects the remaining channels available for activation. Peak inward currents from steady-state slow inactivation were normalized by the maximum current amplitude and fit with a Boltzmann equation,

\[ I = I_{\text{min}} + 1/(1 + \exp[V - V_{1/2}]/k] \]  

(Eq. 4)

where \( I \) is the current amplitude measured during the test depolarization, \( V_{1/2} \) is the midpoint of slow inactivation, and \( k \) is the slope factor. Closed-state inactivation was assessed by stepping from the holding potential to the inactivation potential ranging from −80 mV to −50 mV in 10-mV increments for 1–2049 ms, followed by a −10-mV test pulse for 20 ms to determine the fraction of current inactivated during the prepulse. Ramp currents were elicited with 600-ms slow depolarizations from −120 to 0 mV at a rate of 0.2 mV/ms. The ramp current was normalized to the maximal peak inward current recorded during the activation protocol for each cell.

Structural modeling of the wild-type and mutant Na\textsubscript{v}1.7 channels

We used the X-ray crystal structure of bacterial sodium channel Na\textsubscript{r}Rh (Protein Data Bank code 4DXW) (44) as a template to build the homology of the Na\textsubscript{v}1.7, Na\textsubscript{v}1.7-G856D, and Na\textsubscript{v}1.7-G856R channels to assess structural changes and altered interactions near Gly-856 in S5 of domain II. The RosettaCM protocol (51, 52) was used with the RosettaMembrane scoring function (53–55) to thread the Na\textsubscript{v}1.7 sequence on the Na\textsubscript{r}Rh structure. The extracellular loop regions connecting S5-P1 and S6-P2 were truncated. 10,000 models of the wild-type Na\textsubscript{v}1.7 were generated, and the top 1,000 models were selected based on total Rosetta score and then clustered to identify the most frequently sampled conformations as described previously (56). The G856R and G856D models were created using Rosetta by mutating Gly–856 in the best wild-type Na\textsubscript{v}1.7 model. The Rosetta kinematic loop modeling protocol (57) was used to optimize conformation of the backbone and side chains of 5 amino acids upstream and downstream of position 856 in G856R and G856D models. The figures of models were rendered with University of California, San Francisco Chimera software (58).

Data analysis

The electrophysiological data were analyzed using Fitmaster (HEKA Electronics), Excel, and Origin 8.5 (Northampton, MA) software and presented as means ± S.E. Statistical significance was determined by unpaired Student’s \( t \) test.

Author contributions—B. S. T. designed, performed, and analyzed the electrophysiological experiments. B. S. T. prepared the figures. S. G. W. and S. D. D.-H. conceived the study and designed experiments. B. S. T., S. G. W., and S. D. D.-H. wrote the paper. P. T. N. conducted structural modeling studies and analyzed results. P. T. N. and V. Y.-Y. conceived the structural modeling study, designed experiments, and wrote aspects of the paper. E. Y. Z. acquired patient samples and conducted anthropometric measurements of the proband and family members. E. Y. Z. and Y. Y. wrote aspects of the paper.

Acknowledgments—We thank Fadia Dib-Hajj and Palak Shah for technical support.

References

Na\textsubscript{v}1.7 mutation in pain and underdevelopment of the limbs


Gain-of-function mutation of a voltage-gated sodium channel Nav1.7 associated with peripheral pain and impaired limb development
Brian S. Tanaka, Phuong T. Nguyen, Eray Yihui Zhou, Yong Yang, Vladimir Yarov-Yarovoy, Sulayman D. Dib-Hajj and Stephen G. Waxman

doi: 10.1074/jbc.M117.778779 originally published online April 5, 2017

Access the most updated version of this article at doi: 10.1074/jbc.M117.778779

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2017/04/05/M117.778779.DC1

This article cites 57 references, 18 of which can be accessed free at
http://www.jbc.org/content/292/22/9262.full.html#ref-list-1